Study of Intravenous Tirofiban Followed by Dual Antiplatelet Therapy Compared to Dual Therapy Alone in Adults With Mild Acute Ischemic Stroke

What this Trial Is About

Researchers are evaluating whether starting intravenous tirofiban within 48 hours after mild ischemic stroke symptoms begin, followed by dual antiplatelet therapy DAPT, can improve functional recovery compared to standard DAPT alone. This study focuses on patients with mild stroke symptoms NIHSS score 5 or less who often face risks of early neurological decline and poor outcomes despite current treatments. The trial aims to provide more evidence on tirofibans potential benefits in this group. Participants are randomly assigned to one of two groups one receiving an initial intravenous tirofiban infusion for 48 hours with a specific dosing schedule, then switching to oral dual antiplatelet therapy aspirin and clopidogrel, and the other receiving standard oral dual antiplatelet therapy alone. The trial is open-label with blinded outcome assessment and compares the treatments over the early period following stroke onset. Throughout the study, participants will be monitored for functional outcomes using the modified Rankin Scale at 90 days. Additional assessments include neurological status changes within the first 7 days, stroke recurrence, bleeding events, and cardiovascular outcomes. The trial lasts through 90 days after treatment start, with careful safety and effectiveness evaluations to understand the impact of the treatment approach.

Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke